Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» GSK's phase III study of trametinib and dabrafenib combo shows survival benefit compared to vemurafenib
GSK's phase III study of trametinib and dabrafenib combo shows survival benefit compared to vemurafenib
GSK's phase III study of trametinib and dabrafenib combo shows survival benefit compared to vemurafenib
Submitted by
admin
on July 19, 2014 - 9:20am
Source:
Pharmabiz
News Tags:
trametinib
GSK
vemurafenib
dabrafenib
melanoma
Headline:
GSK's phase III study of trametinib and dabrafenib combo shows survival benefit compared to vemurafenib
Do Not Allow Advertisers to Use My Personal information
